Wealth Enhancement Advisory Services LLC Takes $721,000 Position in TG Therapeutics, Inc. $TGTX

Wealth Enhancement Advisory Services LLC acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 19,747 shares of the biopharmaceutical company’s stock, valued at approximately $721,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TGTX. Jump Financial LLC raised its holdings in shares of TG Therapeutics by 551.8% in the second quarter. Jump Financial LLC now owns 320,022 shares of the biopharmaceutical company’s stock worth $11,518,000 after buying an additional 270,922 shares during the last quarter. Marex Group plc purchased a new position in TG Therapeutics in the 2nd quarter worth $10,017,000. KLP Kapitalforvaltning AS lifted its position in TG Therapeutics by 7.7% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 30,800 shares of the biopharmaceutical company’s stock worth $1,108,000 after acquiring an additional 2,200 shares during the period. Yorktown Management & Research Co Inc purchased a new stake in TG Therapeutics during the 2nd quarter valued at about $383,000. Finally, Prudential Financial Inc. increased its holdings in shares of TG Therapeutics by 5.5% in the second quarter. Prudential Financial Inc. now owns 189,315 shares of the biopharmaceutical company’s stock valued at $6,813,000 after purchasing an additional 9,925 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $29.12 on Thursday. The company has a current ratio of 3.82, a quick ratio of 2.89 and a debt-to-equity ratio of 0.40. TG Therapeutics, Inc. has a 12-month low of $25.28 and a 12-month high of $46.48. The business’s 50 day moving average is $30.52 and its two-hundred day moving average is $31.86. The company has a market capitalization of $4.62 billion, a P/E ratio of 10.47 and a beta of 1.85.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, topping the consensus estimate of $0.24 by $2.19. TG Therapeutics had a return on equity of 133.24% and a net margin of 84.13%.The business had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. During the same period in the prior year, the company posted $0.02 EPS. The business’s quarterly revenue was up 92.7% on a year-over-year basis. Analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $32.57, for a total transaction of $162,850.00. Following the completion of the sale, the director directly owned 223,816 shares in the company, valued at approximately $7,289,687.12. The trade was a 2.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.64% of the company’s stock.

Analyst Upgrades and Downgrades

TGTX has been the subject of a number of research reports. JPMorgan Chase & Co. decreased their target price on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a report on Monday. The Goldman Sachs Group increased their price objective on shares of TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. B. Riley upgraded shares of TG Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $50.00.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.